Stockreport

VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR

Vascular Biogenics Ltd. - Ordinary Shares  (VBLT) 
Last vascular biogenics ltd. - ordinary shares earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: vblrx.com
PDF TEL AVIV, Israel, April 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody th [Read more]